Diabetes Archives

In Depth 25 Jan 2018

What Happened to the Plans for a Smart Contact Lens for Diabetics?

Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google has waned. Why? In 2016, smart wearables growth was steady but a recent study predicts that the market will pick up this year introducing innovative products to the consumer market: according to CCS Insight, the market for […]

January 25, 2018 - 5 minutesmins - By External Contributor

News and Trends 15 Jan 2018

This is Why You Should Avoid Eating too Much Junk Food

Following last week’s article about the importance of eating plenty of fruit and vegetables, German researchers have unearthed another link between junk food and diabetes and heart disease. Researchers from the University of Bonn, Germany, have found that an unhealthy diet can cause the immune system to act as if it is responding to bacterial […]

January 15, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Dec 2017

An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up

Sanofi’s rapid-action insulin, Admelog, will be the first “follow-on” insulin product on the market to help diabetics manage their blood sugar at mealtimes. Sanofi has announced the FDA approval of Admelog, the first “follow-on” mealtime insulin available to type 1 and type 2 diabetics. This gave the company’s stock price a boost of 1.1% this morning, which is […]

December 12, 2017 - 3 minutesmins - By Alex Dale

News and Trends 7 Dec 2017

French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma

Adocia’s rapid-action insulin outperforms Novo Nordisk’s market approved treatment for type 1 diabetes during a Phase I study. Adocia specializes in new formulations of therapeutic proteins, particularly for the treatment of diabetes. Just last week, Adocia’s glucagon treatment for hypoglycemia was proved to be safe in a Phase I study. Today, the biotech has announced that its […]

December 7, 2017 - 3 minutesmins - By Alex Dale

News and Trends 28 Nov 2017

The Link Between Type 2 Diabetes and Obesity may have Finally been Uncovered

Researchers at the Université de Genève have unravelled the cellular and molecular mechanisms linking obesity and insulin resistance. We have long known about a link between obesity and type 2 diabetes, but discovering the underlying mechanisms has proved difficult. A group of researchers at the Université de Genève, Switzerland, may have found a protein that links changes […]

November 28, 2017 - 3 minutesmins - By Alex Dale

News and Trends 21 Nov 2017

Can this French Biotech Make it Easier to Rescue People from Hypoglycemia?

Adocia’s ready-to-use glucagon has proved to be safe in phase I trials. The company believes it can overthrow Novo Nordisk and Eli Lilly in rescuing severe hypoglycemia. Based in Lyon, France, Adocia develops new formulations to improve the performance of diabetes drugs, including an ultra-rapid insulin to help type 1 diabetics control their blood glucose levels […]

November 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

imcyse type 1 diabetes immunotherapy cure

News and Trends 15 Nov 2017

Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure

Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […]

November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2017

It’s World Diabetes Day! But What is Biotech Doing to Fight the Disease?

Diabetes is now a major epidemic, with 425 million people living with the condition. Luckily, biotech is working on ways to stop it in its tracks. Not only is it Antibiotic Awareness Week, but today is World Diabetes Day. This year’s theme draws attention to diabetes in women and the right to live a healthy life. […]

November 14, 2017 - 4 minutesmins - By Alex Dale

News and Trends 2 Nov 2017

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020. Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type […]

November 2, 2017 - 2 minutesmins - By Alex Dale

fecal transplant diabetes netherlands2 1

News and Trends 5 Oct 2017

Dutch Clinical Trial Points to Fecal Transplant as Diabetes Treatment

A small clinical trial in the Netherlands has found that a fecal transplant from a lean donor can temporarily improve diabetes symptoms in obese men. Research published in Cell Metabolism from the University of Amsterdam has found that a fecal transplant from lean men to obese men can cause a short-term improvement in insulin resistance. This […]

October 5, 2017 - 3 minutesmins - By Alex Dale

Boehringer Ingelheim Zealand Pharma diabetes

News and Trends 23 Aug 2017

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting […]

August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Novo Nordisk Semaglutide GLP 1 receptor agonist type 2 diabetes Eli Lilly Trulicity dulaglutide

More News! 18 Aug 2017

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo Nordisk’s semaglutide with Eli Lilly’s Trulicity (dulaglutide), already in the market, have revealed that Novo’s […]

August 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us